Abstract: A circularly polarized radiating element includes at least one excitation aperture for a wave that is linearly polarized with what is referred to as an excitation first polarization, a frequency selective surface and a metasurface comprising a two-dimensional and periodic array of metasurface cells, the excitation aperture opening onto the metasurface, the metasurface cells all being oriented identically with respect to the excitation polarization and configured to: reflect an incident wave having the excitation polarization in order to form a reflected wave polarized with the excitation polarization, and depolarize and reflect the incident wave in order to form a reflected wave polarized with the orthogonal polarization, having a phase difference substantially equal to ±90° with respect to the reflected wave polarized with the excitation polarization, and having an amplitude substantially equal to the amplitude of a wave radiated by the frequency selective surface, generated from the reflected wave polarized

Abstract: The production of an oxygen-absorbent composition is provided, having: (a) a porous silica encapsulation matrix; and (b) a composition containing an oxygen-absorbent compound selected from fatty acids, unsaturated esters or compounds containing same, and, optionally, a catalyst based on an inorganic salt of a transition metal, wherein the composition (b) is encapsulated in the porous silica matrix (a). The composition can form part of the structure of the packaging for oxidation sensitive products or be placed in the surrounding atmosphere to reduce the concentration of oxygen. A method for encapsulating the active compound or the active compound together with a catalyst, and subsequently incorporating same into polymer matrices is also provided.

Abstract: The present invention relates to a family of compounds derived from 5-bromo-7-azaindole to which alkyl chains have been incorporated in one of the nitrogens to make them soluble in organic solvents as well as the incorporation in the position 5 of 4-(diphenylamino)phenylboronic acid derivatives. These structural modifications increase the emission of the derivative in a solid state. The incorporation of aldehyde and 2-cyano-but-2-enoic acid derivatives in position 3 facilitates the attachment thereof in different systems. Given this characteristic, they may be applicable in the development of solid-state luminescent materials used in applications of detection, biomedical applications, solid-state illumination, as well as optoelectronic devices.

Abstract: The present invention provides 5-(4-(2-(5-(1-hydroxyethyl)pyridine-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione and novel stereoisomers of said compound for use in the treatment of central nervous system (NS)disorders.

Abstract: The invention relates to: a compound derived from 7,7?-diazaisoindigo; an organogel, formed by these compounds, having an aggregation-induced emission (AIE) in the red region of the visible spectrum (600-800 nm); and a xerogel produced by drying said organogel. Due to these properties, said organogel or xerogel can be applied to optoelectronic devices or fluorescent sensors.

Abstract: The present invention relates to the use of a fructooligosaccharide (FOS) comprising from 2 to 10 monosaccharide units, as an elicitor of the mechanisms of absorption of mineral elements from the soil, and of the defense mechanisms against pathogens. It also relates to a fertilizing and biostimulating composition containing these fructooligosaccharides, and to the use thereof in a method for treating crop plants.

Abstract: A dynamic approach to optimizing configuration of network parameters is presented. By gathering operational contexts and aggregating optimized network performance data against a baseline, a training data set may be generated. Client-side policies are determined, in part, by applying machine learning techniques on the training data set to achieve desired outcomes. Data delivery strategies are compiled at user devices to deliver content using the optimized network configuration values based on the operating contexts.

Abstract: Airborne systems and methods for the detection, location and obtaining of images of buried objects and for the characterization of the composition of the subsoil. The systems comprise at least one aerial module with a radar unit that emits and/or captures radar signals and a positioning and guidance system with an accuracy equal to or less than 3 cm, and a ground station with a flight control system and a radar signal processing unit where radar signal processing algorithms are applied. The invention also comprises a method for the detection, localization and obtaining of images of buried objects and a method for the characterization of the composition of the subsoil. Applicable in sectors where it is necessary to perform the detection of buried objects, as for example in civil applications (detection of antipersonnel mines), pipeline inspection or in archaeology.

Abstract: The present invention provides 5-(4-(2-(5-(1-hydroxyethyl)pyridine-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione and novel stereoisomers of said compound for use in the treatment of central nervous system (NS) disorders.

Abstract: Compounds of general formula (I): R1—Wn—Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-Yp—Zq—R2, their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.

Abstract: Method of diagnosing fibromyalgia based on microRNAs. The invention provides a method for the molecular diagnosis of fibromyalgia patients, based on the analysis of the possible alteration of the levels of specific microRNAs in peripheral blood mononuclear cells. The method comprises the analysis of the levels of the microRNAs miR-223, miR-451, miR-338, miR-143 and miR-145 and the diagnosis of fibromyalgia when at least one, or preferably several thereof have decreased levels with respect to a reference value, which preferably is the level of each microRNA in healthy individuals. Three additional microRNAs are also provided, miR-21, miR-1260b and miR-1908, which can be used as negative controls to confirm the diagnosis. The method facilitates an objective diagnosis of fibromyalgia based on molecular markers that are determined from a sample such as blood, which is easy to obtain and process.

Abstract: A system for improving network data communications performance between end-user devices and content origin servers. A plurality of accelerators are distributed across a network and communicate with end-user devices and content origin servers. Software development kits installed on end-user devices monitor control channel data traffic between the end-user devices and accelerators. Various data traffic efficiency approaches are implemented by the software development kits on the end-user devices and the plurality of accelerators resulting in improved data communications links between the end-user devices and the content origin servers.

Abstract: The present invention provides 5-(4-(2-(5-(1-hydroxyethyl)pyridine-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione and novel stereoisomers of said compound for use in the treatment of central nervous system (NS) disorders.

Abstract: Novel compounds for use in cognition improvement It relates to certain compounds having a polycyclic structure and a —(C?O)NRaRb moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurode-generative diseases.

Abstract: On example of a fluid dispensing system includes an unfiltered water container body defining an internal storage volume configured to hold a volume of water, a fluid outlet arranged for fluid communication with the internal storage volume, and a filter element positioned in the internal storage volume. With this configuration, a water dispensing process can be performed in which a single continuous stream of unfiltered water from the unfiltered water container body can pass through the filter element and be dispensed from the unfiltered water container body as a stream of filtered water. A water soluble tablet with an additive is positioned in the internal storage volume downstream of the filter medium such that the filtered water can pass out of the filter element and into contact with the water soluble tablet before being dispensed from the fluid outlet.

Abstract: A system for improving network data communications performance between end-user devices and content origin servers. A plurality of accelerators are distributed across a network and communicate with end-user devices and content origin servers. Software development kits installed on end-user devices monitor control channel data traffic between the end-user devices and accelerators. Various data traffic efficiency approaches are implemented by the software development kits on the end-user devices and the plurality of accelerators resulting in improved data communications links between the end-user devices and the content origin servers.

Abstract: The present invention relates to a family of S-substituted quinazoline derivatives that inhibitors of the enzyme phosphodiesterase 7 (PDE7), useful for the treatment or prevention of diseases mediated by said enzyme, especially inflammatory, neurodegenerative, neurological, psychiatric and/or autoimmune diseases.

Abstract: The present invention provides 5-(4-(2-(5-(1-hydroxyethyl)pyridine-2-yl)ethoxy) benzyl)thiazolidine-2,4-dione and novel stereoisomers of said compound for use in the treatment of central nervous system (NS) disorders.

Abstract: Compounds of general formula (I): R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.

Abstract: The invention relates to a product that comprises a compound of formula (1-01) to (1-47) and a compound of formula (2-01) to (2-26), or their pharmaceutically or veterinary acceptable salts thereof, or any stereoisomers either of the compounds or of any of their pharmaceutically or veterinary acceptable salts. The invention also relates to said product for use in the treatment and/or prevention of a neurological disorder coursing with a cognition deficit or impairment, or a neurodegenerative disease.